Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Medical Oncology
Obesity Medicine
Questions discussed in this category
How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...
1 Answer available
16828
Papers discussed in this category
BMC endocrine disorders, 2024 Nov 18
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.
International urology and nephrology, 2024 Nov 04
Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.
Cancers, 2024 Sep 22
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
Related Topics in Medical Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers